A

mid rising tension between drug makers and compound pharmacies, the Food and Drug Administration has issued new policies that seek to bolster manufacturing standards for compounded medicines and, in the process, may serve to establish competitive boundaries between these rival sets of companies.

A key piece of the effort focuses on a contentious issue: compounded drugs that, essentially, may be copies of prescription medicines. The agency specifies that compounders should not copy FDA-approved drugs, except when shortages exist.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Anyone concerned about patient health and the cost of prescription drugs should fight this, including payers, insurers, employers, physicians and patients. There are plenty of patients who cannot tolerate some of the additives in prescription drugs, or need different formulations or dosages. Once again, FDA reveals its true colors as an agency more protective of industry interests than patient health. It is captured nearly lock, stock and barrel by the ‘stakeholders’ that benefit from the status quo and tightening the screws to lock down their monopolies, patents and rights to sell dangerous devices that are now banned or withdrawn from sale in other nations given the extent of patient harm.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.